Create a Profile
Create a Profile
Get In Touch Mobile
Accel Research Sites now recruiting for new COVID-19 vaccine trial for adults
Although select vaccines were approved for emergency use, the fight against COVID-19 is not over.
Accel Research Sites will serve as another location for a new adult clinical trial for COVID-19 vaccine candidates. The company is now recruiting adults 18 and older for a new COVID-19 clinical trial. Enrollment is now open.
The study will take place at Accel’s Birmingham, AL location. Dr. Hayes T. Williams will serve as the primary investigator for this trial.
Accel Research Site’s Birmingham, AL location was the first in the state to start To start clinical trials for COVID-19 Vaccines in July 2020.
Dr. Hayes T. Williams has been involved in the development of multiple COVID-19 vaccines from the beginning. He has worked on numerous vaccines that were approved for emergency use and trials going through the approval process now including Pfizer, Moderna, Novavax and Johnson & Johnson among others.
“Accel Research Sites is excited to continue to be a part of the solution for COVID-19,” said Lora Parahovnik, CEO of Accel Research Sites. “We will continue to work with pharmaceutical companies and primary investigators in the development of vaccines in hopes to reach herd immunity.”
Adults who are interested in participating in the study can visit accelresearchsites.com. An Accel staff member will reach out to further evaluate eligibility and qualifications to enter the study.
Accel Research Sites seeks to enroll a wide variety of participants for the trials, including racial and ethnic minorities.
Accel Research Sites provides novel treatment options in all major therapeutic areas. It has more than 30 locations, including a 62-bed Phase 1 unit in Florida and units in Georgia and Alabama.
Ready to be part of healthcare history? Find the right clinical trial for you.